The worldwide ocular implant market is divided into corneal implants, middle and extruded lenses, and bifocal lenses. Each category features different functionalities, thus increasing the chances for finding a matching eye implant for the patient's requirements. The demand for these in the market has grown tremendously due to its promising effects and favorable outcomes. This is the reason that it has been ranked as one of the top choices of patients who are suffering from eye defects. Some of the common types of ocular implants in the market include
Corneal Implants: A cornea transplant is a surgical procedure to replace part of your cornea with corneal tissue from a donor. With increasing number of advancements in technology, the surgical procedure is being made easier and safer for the patients. According to the latest statistical data, the demand for ocular implants has been increasing steadily in the world as per the latest surveys. The global ocular implant market can be broadly classified into five sectors - intraocular lenses (IOL), eye surgery lenses (GL), bifocal lenses (BFL), and laser eye surgery glasses. Moreover, there is an increasing number of manufacturers in this field.
Moreover, increasing prevalence of ocular dysfunction and disorder is expected to drive growth of the global ocular implant market. For instance, in January 2019, according to Glaucoma research foundation, currently, there are over 3 million people in the U.S. that have been diagnosed with glaucoma. The National Eye Institute projects that this number will be increased by 58% and expected to reach 4.2 million by 2030.
Increasing number of research and development activities to develop innovative ocular implant is contributing to growth of global ocular implant market. For instance, in July 2018, Genentech, Inc. announced positive results for Phase II clinical trial study conducted to evaluate the safety and efficacy of the investigational Port Delivery System (PDS) with Ranibizumab, the first-ever eye implant to achieve sustained delivery of a biologic medicine, in people with wet age-related macular degeneration (AMD)
No comments:
Post a Comment